Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently ...

CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.

Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...